Lonza Invests CHF 20 million to Expand API Development and Manufacturing Facility in Nansha, China
New investments will include three 1,000L GMP trains with an overall 12m3 of reactor volume
Lonza
The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. The additional GMP laboratories will be able to develop and manufacture highly potent API (HPAPI) under GMP standards.
Lonza’s Nansha site is fully integrated within the company’s global manufacturing network. Scientists and engineers based in Nansha focus on API development and manufacturing for customers around the globe. The Lonza team also contains regulatory specialists with experience working with Chinese regulators throughout the drug development and scale-up process. Approximately 250 employees work at Lonza’s Nansha site; this expansion is expected to create around 70 new positions.
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022.
Other news from the department business & finance
These products might interest you
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.